Keeler Thomas Management LLC Trims Stake in Repligen Corporation (NASDAQ:RGEN)

Key Points

• Keeler Thomas Management LLC sold 4,100 shares of Repligen Corporation, reducing its stake by 45.7% and now owns 4,879 shares valued at approximately $621,000.
• Analysts have mixed opinions on Repligen, with Royal Bank Of Canada raising its target price to $204.00 and others like Wells Fargo & Company lowering theirs to $175.00, reflecting varied confidence in the stock's performance.
• Repligen reported an earnings miss with $0.37 EPS for the quarter, below the expected $0.40, despite a 14.8% year-over-year revenue increase, totaling $182.37 million.

Keeler Thomas Management LLC trimmed its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 45.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,879 shares of the biotechnology company's stock after selling 4,100 shares during the quarter. Keeler Thomas Management LLC's holdings in Repligen were worth $621,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD raised its position in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after acquiring an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. raised its position in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after acquiring an additional 594,189 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Repligen during the fourth quarter valued at approximately $53,428,000. Raymond James Financial Inc. purchased a new position in Repligen during the fourth quarter valued at approximately $52,492,000. Finally, Marshall Wace LLP raised its position in Repligen by 73.8% during the fourth quarter. Marshall Wace LLP now owns 412,235 shares of the biotechnology company's stock valued at $59,337,000 after acquiring an additional 175,013 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

NASDAQ RGEN traded down $2.09 during trading hours on Friday, hitting $111.43. 635,942 shares of the company's stock traded hands, compared to its average volume of 1,059,227. The company has a market capitalization of $6.26 billion, a PE ratio of -445.70, a PEG ratio of 2.09 and a beta of 1.05. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The firm's 50-day moving average is $122.76 and its 200-day moving average is $134.58.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same quarter last year, the company earned $0.40 earnings per share. Repligen's revenue for the quarter was up 14.8% on a year-over-year basis. Equities analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on RGEN shares. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Barclays assumed coverage on Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price objective for the company. Evercore ISI cut their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Canaccord Genuity Group cut their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, Royal Bank Of Canada boosted their price objective on Repligen from $193.00 to $204.00 and gave the company an "outperform" rating in a research report on Wednesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.